adalimumab-ryvk — CareFirst (Caremark)

Initial criteria

• Requested medication is used for immune checkpoint inhibitor-related inflammatory arthritis

Reauthorization criteria

• Member achieves or maintains a positive clinical response as evidenced by low disease activity or improvement in signs and symptoms

Approval duration

12 months